Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

517

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

517 results for “Checkpoint inhibitors”

Learn how ShareScore rates datasets ↗
geo16/100

Tumor-intrinsic ETV5 Expression Promotes MDSCs-mediated Immune Evasion and Immune Checkpoint Inhibitor Resistance

GEO Series GSE286508. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenFeb 2026View details →
geo16/100

Transcriptomic and metabolic effect of immune checkpoint inhibitors on cellular components in renal cell tumor microenvironment and in Sunitinib resistant renal cell carcinoma [III]

GEO Series GSE226968. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2024View details →
geo16/100

Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis

GEO Series GSE205501. Homo sapiens. 86 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2023View details →
geo16/100

Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy [RNA-seq (human)]

GEO Series GSE192580. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2023View details →
geo16/100

Engineered Nanobodies Targeting Endogenous Digoxin-like Substances Function as Novel Immune Checkpoints Inhibitors and Enhance Immunotherapy against Cancer Metastasis

GEO Series GSE308031. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2025View details →
geo16/100

First-in-class microbial ecosystem therapeutics 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumours (MET4-IO Trial)

GEO Series GSE199245. human feces metagenome. 170 samples. Type: Other.

openGEO-OpenMar 2022View details →
geo16/100

Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma

GEO Series GSE270047. Homo sapiens. 434 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2024View details →
geo16/100

Transcriptomic and metabolic effect of immune checkpoint inhibitors on cellular components in renal cell tumor microenvironment and in Sunitinib resistant renal cell carcinoma

GEO Series GSE226969. Homo sapiens. 36 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2024View details →
geo16/100

Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (human)

GEO Series GSE122220. Homo sapiens. 10 samples. Type: Expression profiling by array.

openGEO-OpenNov 2020View details →
geo16/100

Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer [RNA-seq]

GEO Series GSE196323. Homo sapiens; Mus musculus. 55 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2022View details →
geo16/100

Molecular mechanisms of PD-1 immune checkpoint inhibitors in mouse mammary tumours

GEO Series GSE268752. Mus musculus. 20 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2024View details →
geo16/100

Single-cell transcriptome profiles of tumor tissues from lung cancer patients receiving immune checkpoint inhibitors.

GEO Series GSE205335. Homo sapiens. 33 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenNov 2024View details →
geo16/100

Transcriptomic and metabolic effect of immune checkpoint inhibitors on cellular components in renal cell tumor microenvironment and in Sunitinib resistant renal cell carcinoma [1]

GEO Series GSE226965. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2024View details →
geo16/100

Engineered Nanobodies Targeting Endogenous Digoxin-like Substances Function as Novel Immune Checkpoints Inhibitors and Enhance Immunotherapy against Cancer Metastasis

GEO Series GSE308027. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2025View details →
geo16/100

Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury [bulk RNA-seq]

GEO Series GSE287540. Homo sapiens. 128 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJan 2025View details →
geo16/100

Tumor regression of recurrent chemo-resistant placental site trophoblastic tumor after anti-PD-1 immune checkpoint inhibitor therapy

GEO Series GSE128222. Homo sapiens. 2 samples. Type: Expression profiling by array.

openGEO-OpenJan 2025View details →
geo16/100

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-type Non-Small Cell Lung Cancer

GEO Series GSE274960. Mus musculus. 19 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2024View details →
geo16/100

Clonal CD8 T cells orchestrate arrhythmogenic inflammation in immune checkpoint inhibitor-associated myocarditis

GEO Series GSE299032. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing; Other.

openGEO-OpenJun 2025View details →
zenodo16/100

IFN-γ signature as a peripheral blood biomarker for immune checkpoint inhibitors outcomes

Open the record for dataset details and reuse information.

restrictedcc-by-4.0Mar 2024View details →
zenodo16/100

Dataset related to article "Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors"

<p>This record contains raw data related to article &ldquo;Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors&quot;</p> <p><strong>Introduction: </strong> In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI).</p> <p><strong>Methods: </strong> Data from fifty NSCLC patients referred for ICI between December 2015 and May 2019 were analyzed. All patients underwent 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) and contrast-enhanced CT at baseline and for response assessment after 6-8 weeks. Patients who received ATB within 1 month before or after the first dose of ICI were compared with those who did not. Response assessment according to iRECIST and EORTC was evaluated, as well as progression-free survival (PFS) and overall survival (OS). For semi-quantitative parameters, we computed metabolic tumor volume (MTV), total lesion glycolysis (TLG) and their variations (∆).</p> <p><strong>Results: </strong> Twenty NSCLC cases of 50 (40%) had received ATB. Patients receiving ATB had a higher number of metastases (<em>p</em> = 0.046), and were associated with an elevated tumor burden, expressed by TLG (687 vs. 235.3, <em>p</em> = 0.007) and MTV (125.6 vs. 40.6, <em>p</em> = 0.002), compared to no-ATB patients. According to iRECIST, progressive disease rate was significantly higher for ATB group (64.7% vs. 27.6%, <em>p</em> = 0.029). Likewise, PFS was shorter for ATB compared to no-ATB (median 4.1 vs. 12.4 months, <em>p</em> = 0.004), while no difference for OS was detected. On multivariate analysis, the effect of ATB remained significant for poor PFS along with performance status (ECOG &ge; 1), and ∆SUVmax.</p> <p><strong>Conclusions: </strong> ATB therapy seems to be associated with a worse treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with ICI.</p>

restrictedFeb 2022View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record